ScholarMate
English简体中文繁體中文
Customer service: 400-1616-289
Sign inSign up
Journal article

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Wang, Yingdan; Zhang, Xiang; Ma, Yunping; Wang, Yanqun; Zhan, Wuqiang; Zheng, Qinwen; Zhang, Meng; Ji, Ping; Liu, Mei; Liu, Qianying; Sun, Tingting; Zhu, Tongyu; Wen, Yumei; Sun, Lei*; Zhao, Jincun*; Wu, Fan*; Chen, Zhenguo*; Huang, Jinghe*复旦大学; 广州医学院; 上海交通大学; 中国医学科学院; 1; 5
Cell Discovery2022-10-7DOI: 10.1038/s41421-022-00463-6
8Cited by7Reads
CiteSave
Share

Abstract

The highly mutated and transmissible Omicron (BA.1) and its more contagious lineage BA.2 have provoked serious concerns over their decreased sensitivity to the current COVID-19 vaccines and evasion from most anti-SARS-CoV-2 neutralizing antibodies (NAbs). In this study, we explored the possibility of combating the Omicron and BA.2 by constructing bispecific antibodies based on non-Omicron NAbs. We engineered 10 IgG-like bispecific antibodies with non-Omicron NAbs named GW01, 16L9, 4L12, and REGN10987 by fusing the single-chain variable fragments (scFvs) of two antibodies through a linker and then connecting them to the Fc region of IgG1. Surprisingly, 8 out of 10 bispecific antibodies showed high binding affinities to the Omicron receptor-binding domain (RBD) and exhibited extreme breadth and potency against pseudotyped SARS-CoV-2 variants of concern (VOCs) including Omicron and BA.2, with geometric mean of 50% inhibitory concentration (GM IC50) values ranging from 4.5 ng/mL to 103.94 ng/mL, as well as the authentic BA.1.1. Six bispecific antibodies containing the cross-NAb GW01 not only neutralized Omicron and BA.2, but also neutralized the sarbecoviruses including SARS-CoV and SARS-related coronaviruses (SARSr-CoVs) RS3367 and WIV1, with GM IC50 ranging from 11.6 ng/mL to 103.9 ng/mL. Mapping analyses of 42 spike (S) variant single mutants of Omicron and BA.2 elucidated that these bispecific antibodies accommodated the S371L/F mutations, which were resistant to most of the non-Omicron NAbs. A cryo-electron microscopy (cryo-EM) structure study of the representative bispecific antibody GW01-16L9 (FD01) in its native full-length IgG form in complex with the Omicron S trimer revealed 5 distinct trimers and one novel trimer dimer conformation. 16L9 scFv binds the receptor-binding motif (RBM), while GW01 scFv binds a epitope outside the RBM. Two scFvs of the bispecific antibody synergistically induced the RBD-down conformation into 3 RBD-up conformation, improved the affinity between IgG and the Omicron RBD, induced the formation of trimer dimer, and inhibited RBD binding to ACE2. The trimer dimer conformation might induce the aggregation of virions and contribute to the neutralization ability of FD01. These novel bispecific antibodies are strong candidates for the treatment and prevention of infection with the Omicron, BA.2, VOCs, and other sarbecoviruses. Engineering bispecific antibodies based on non-Omicron NAbs could turn the majority of NAbs into a powerful arsenal to aid the battle against the pandemic.

Disciplines and keywords

Keywords
CONVALESCENT
Related
Loading…

Could not load papers. Please retry.

Retry

Publication info

Publication status
Published
Journal
Cell Discovery
Publication date
2022-10-07
Volume / issue
Vol. 8, Issue 1
Pages
104
DOI
10.1038/s41421-022-00463-6
Journal ranking
Q1
Output indexing
SCIE
Funding acknowledgment
Shanghai Municipal Science and Technology Major Project [ZD2021CY001]; National Natural Science Foundation of China [31771008, 3197014]; National Science and Technology Major Project of China [2017ZX10202102, 2018ZX10301403]; Ministry of Science and Technology of China [2021YFC2302500]; Shanghai Municipal Commission of Health and Family Planning [2018BR08]; Chinese Academy of Medical Sciences [2019PT350002]

Authors

  • W

    Wang, Yingdan (First author)

    5 · b · fudan univ · cams

  • Z

    Zhang, Xiang

    5 · b · fudan univ · cams

View all 18 authorsShow fewer authors
  • M

    Ma, Yunping

    5 · b · fudan univ · shanghai jiao tong univ · cams

  • W

    Wang, Yanqun

    1 · guangzhou med univ

  • Z

    Zhan, Wuqiang

    5 · b · fudan univ · cams

  • Z

    Zheng, Qinwen

    5 · b · fudan univ · cams

  • Z

    Zhang, Meng

    5 · b · fudan univ · cams

  • J

    Ji, Ping

    5 · b · fudan univ · cams

  • L

    Liu, Mei

    5 · b · fudan univ · cams

  • L

    Liu, Qianying

    5 · b · fudan univ · cams

  • S

    Sun, Tingting

    5 · b · fudan univ · cams

  • Z

    Zhu, Tongyu

    5 · b · fudan univ · cams

  • W

    Wen, Yumei

    5 · b · fudan univ · cams

  • S

    Sun, Lei (Corresponding)

    5 · b · fudan univ · cams

  • Z

    Zhao, Jincun (Corresponding)

    guangzhou med univ · 1

  • W

    Wu, Fan (Corresponding)

    shanghai jiao tong univ

  • C

    Chen, Zhenguo (Corresponding)

    5 · b · fudan univ · cams

  • H

    Huang, Jinghe (Corresponding)

    5 · b · fudan univ · cams

Sign in for more features

  • Save this paper in My collections
  • Claim your outputs and generate promotion materials
  • Follow authors for new outputs
  • Join groups and collaborate
Sign up / Sign in

Products

  • ScholarMate
  • InnoCity
  • IRISaaS

Support

  • Help Center
  • Privacy Policy
  • Terms of Service

Contact

Online support: []
Customer service: 400-1616-289
Email: support@scholarmate.com

Follow or download ScholarMate

WeChat QR code
WeChat official account
App download QR code
Download the app
OutputsResearchersResearch institutionsResearch newsIRISaaS

©2026 深圳市科研之友网络服务有限公司

Public security registration badge粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417